These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 28829863)

  • 1. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 4. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 5. Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber MR; Nickonchuk T; Turgeon R
    Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
    [No Abstract]   [Full Text] [Related]  

  • 6. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.
    Whayne TF
    Drugs; 2018 Mar; 78(3):287-291. PubMed ID: 29396831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 10. Are PCSK9 Inhibitors Cost Effective?
    Korman MJ; Retterstøl K; Kristiansen IS; Wisløff T
    Pharmacoeconomics; 2018 Sep; 36(9):1031-1041. PubMed ID: 29777433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 15. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
    Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 19. PCSK9 inhibitors and managing cost in the managed care setting.
    Stadler SL; Cook TJ
    Am J Manag Care; 2017 Jun; 23(9 Suppl):S149-S155. PubMed ID: 28978220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub WS; Gidding SS
    Pharmacoeconomics; 2016 Mar; 34(3):217-20. PubMed ID: 26689785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.